Compare AbCellera Biologics Inc (ABCL) vs Canadian National Railway Co. (CNI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbCellera Biologics Inc vs Canadian National Railway Co. — how do they compare? AbCellera Biologics Inc trades at $9.23 (market cap $2.99B), while Canadian National Railway Co. trades at $126.3 (market cap $76.28B). The key difference: Canadian National Railway Co. is far larger — about 25.5× AbCellera Biologics Inc's market cap, and Canadian National Railway Co. pays a 2.06% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | CNI | |
|---|---|---|
Market Cap | $2.99B | $76.28B |
Sector | Health | Industrials |
52-Week High | $9.76 | $130.58 |
52-Week Low | $2.78 | $90.91 |
Enterprise Value | $2.58B | $92.31B |
Dividend Yield | — | 2.06% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) surged 34.78% to $9.34, driven by positive Phase 2 trial results for its menopause drug ABCL635. Despite negative net income margins and cash burn, analyst consensus is strongly bullish with a $15.50 price target. The stock shows a bullish technical trend, with support at $8 and resistance at $10, though RSI levels indicate overbought conditions.
The outlook hinges on ABCL635's clinical progress and future revenue potential, but high valuation ratios and persistent losses pose significant risks. Investor sentiment is optimistic due to recent drug trial success, yet the company must demonstrate a path to profitability to justify current market enthusiasm.
Canadian National Railway (CNI) trades at $125.14, down 1.15% with a bearish technical signal. The company reported strong Q2 2026 results with EPS of $1.50 beating estimates by 7.9% and raised full-year guidance, driven by record grain volumes and improved operational efficiency. Fundamentals show solid profitability with 26.92% net margin and 22.02% ROE, though valuation multiples appear elevated with P/E of 22.62. Recent news highlights continued infrastructure investment and customer growth projects exceeding $2 billion in 2025.
CNI presents a mixed outlook with strong operational execution offset by valuation concerns. The 21.8% upside to consensus price target of $152.38 offers potential, but rising debt levels and competitive pressures pose risks. Analyst sentiment is cautious with 60.79% hold ratings, suggesting waiting for clearer evidence of sustained earnings growth before committing new capital.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Canadian National Railway Co.
Canadian National's railway spans Canada from coast to coast and extends through Chicago to the Gulf of Mexico. In 2019, CN delivered almost 6 million carloads over its 19,600 miles of track. CN generated roughly CAD 14 billion in total revenue by hauling intermodal containers (25% of consolidated revenue), petroleum and chemicals (21%), grain and fertilizers (16%), forest products (12%), metals and mining (11%), automotive shipments (6%), and coal (4%). Other items constitute the remaining revenue.
Read more on CNI →
